Athersys Total Assets 2011-2026 | ATHX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Athersys

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
60.2 M	59.7 M	41.7 M	61.7 M	33.6 M	19.1 M	25.1 M	28.7 M	34.2 M	27.6 M	15.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
61.7 M	15.7 M	37 M

Quarterly Total Assets Athersys

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.43 M	10.5 M	21.6 M	27.7 M	35.5 M	35.2 M	45 M	60.2 M	72.1 M	73.3 M	72.3 M	59.7 M	59.7 M	59.7 M	59.7 M	41.7 M	41.7 M	41.7 M	41.7 M	61.7 M	61.7 M	61.7 M	61.7 M	33.6 M	33.6 M	33.6 M	33.6 M	19.1 M	19.1 M	19.1 M	19.1 M	25.1 M	25.1 M	25.1 M	25.1 M	28.7 M	28.7 M	28.7 M	28.7 M	34.2 M	34.2 M	34.2 M	34.2 M	27.6 M	27.6 M	27.6 M	27.6 M	15.7 M	15.7 M	15.7 M	15.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
73.3 M	7.43 M	36.3 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Adaptimmune Therapeutics plc ADAP	283 M	-	-15.15 %	$ 60.3 M	Britain
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
ANI Pharmaceuticals ANIP	1.28 B	$ 80.34	-	$ 1.55 B	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Aptorum Group Limited APM	16.1 M	$ 0.84	1.96 %	$ 4.58 M	China
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Adagene ADAG	89.3 M	$ 2.67	-	$ 150 M	China
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.57	-	$ 8.59 B	Australia
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	608 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	242 M	$ 1.5	-	$ 281 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Ascendis Pharma A/S ASND	1.18 B	$ 222.03	-	$ 5 B	Danmark
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	22.5 B	$ 110.34	-	$ 27.2 B	Germany
Cabaletta Bio CABA	254 M	$ 2.44	-	$ 2.85 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
Burford Capital Limited BUR	3.11 B	$ 8.97	-	$ 1.44 B	Britain
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 4.22	-	$ 9.18 B	Israel
Autolus Therapeutics plc AUTL	783 M	$ 1.46	-	$ 373 M	Britain
Compugen Ltd. CGEN	115 M	$ 1.71	-	$ 153 M	Israel
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.52	-	$ 4.49 B	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel